Catalog No.
Product Name
Application
Product Information
Citations
-
Dopamine Receptor Agonist
Preclamol is a potent dopamine receptor agonist that stimulates both autoreceptors and postsynaptic receptors. It has been shown to inhibit locomotor activity in rodent models at low doses, making it a valuable tool for studying dopaminergic signaling and related behavioral effects. This compound is useful in research related to neuropharmacology and the exploration of dopamine-related disorders. -
D1 Dopamine Receptor Antagonist
(R)-SKF 38393 hydrochloride is a potent and selective antagonist of the D1 dopamine receptor. This compound effectively inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels, making it a valuable tool for exploring dopamine signaling pathways. It is commonly used in research applications focused on neuropharmacology and the modulation of dopaminergic systems. -
D2 Receptor Agonist
Carmoxirole is a selective peripheral dopamine D2 receptor agonist, demonstrating antihypertensive properties in vivo. This compound is valuable for research into the modulation of cardiovascular functions and the mechanisms underlying hypertension. Its targeted action on the D2 receptor makes it a useful tool for investigating dopaminergic signaling pathways. -
Dopamine Receptor Agonist
(R)-SKF-81297 hydrobromide is the R-enantiomer of SKF-81297, acting primarily as a selective agonist for the dopamine D1 receptor. It demonstrates key biological activities related to the modulation of dopaminergic signaling pathways. This reagent is valuable in research applications focusing on neuropharmacology, including studies on dopamine-related disorders and the exploration of its effects on cognition and behavior. -
Neuroleptics
Prosulpride is a neuroleptic compound that selectively antagonizes dopamine receptors, primarily targeting D2 and D3 subtypes. It exhibits significant antipsychotic properties, making it relevant for the treatment of various psychiatric disorders. Prosulpride is utilized in research to explore dopaminergic signaling pathways and to investigate its therapeutic potential in conditions such as schizophrenia and mood disorders. -
Dopamine Receptor Antagonist
JHW007 hydrochloride is a selective antagonist of dopamine receptors, primarily targeting the D2 subtype. It demonstrates notable activity in modulating neurotransmitter release and has been investigated for its potential effects in cocaine-related research. This compound is valuable for studies exploring addiction mechanisms and neuropharmacology. -
Dopamine Receptor Antagonist
(-)-GSK598809 is a selective antagonist of the dopamine D3 receptor (DRD3). This compound exhibits potent inhibition of DRD3 activity, making it a valuable tool for research into neuropsychiatric disorders and addiction. Its specificity for DRD3 allows for detailed investigations into dopamine-related signaling pathways and their implications for various therapeutic areas. -
Dopamine Receptor Agonist
Bromocriptine is a potent agonist of the dopamine D2 and D3 receptors, exhibiting a high binding affinity with a pKi of 8.05 ± 0.2. This compound is primarily utilized in research to investigate dopaminergic signaling pathways and their implications in various neurological and psychiatric disorders. It is also employed in studies related to endocrine functions, particularly in conditions such as hyperprolactinemia and Parkinson's disease. -
Dopamine Receptor Inhibitor
Seproxetine hydrochloride is a dopamine receptor inhibitor known for its selective serotonin reuptake inhibitory activity. By specifically blocking the serotonin uptake transporter, it increases serotonin levels in the brain, while also exhibiting significant interactions with dopamine receptors. This compound is actively researched for its potential therapeutic applications in mood disorders and associated neurological conditions, showcasing enhanced biological activity and efficacy through its ability to form stable charge transfer complexes. -
Dopamine Receptor Antagonist
Nor-SCH-12679 maleate is a dopamine receptor antagonist that plays a crucial role in research focused on dopaminergic signaling pathways. By inhibiting dopamine receptor activity, it can counteract the stimulatory effects of other compounds, such as peppermint oil, on locomotor activity in experimental models. This compound is valuable for studies investigating the modulation of behavior and neuropharmacological effects related to dopamine signaling. -
Dopamine Receptor Antagonist
JNJ-37822681 is a fast-dissociating antagonist of the D2 dopamine receptor, primarily employed in the research of schizophrenia. This compound demonstrates high specificity for D2 receptors and effectively increases levels of extracellular serotonin, dopamine, and norepinephrine within the rat cerebral cortex. Additionally, JNJ-37822681 exhibits antidepressant-like effects in the mouse tail suspension test while achieving favorable brain distribution and minimizing prolactin release, making it a valuable tool for neuroscience research. -
PF-06256142 Enantiomer
(R)-PF-06256142 is the R enantiomer of PF-06256142, selectively acting as an orthosteric agonist for the D1 dopamine receptor. This compound demonstrates significant potential in modulating receptor desensitization compared to dopamine and other catechol-containing agonists. Its properties make it a valuable tool for research into dopamine-related signaling pathways and receptor pharmacology. -
Dopamine D2/D3 Receptor Antagonist
Raclopride tartrate is a selective antagonist of the dopamine D2 and D3 receptors, exhibiting high binding affinity with Ki values of 1.8 nM and 3.5 nM, respectively. This compound demonstrates potential antipsychotic effects and is primarily utilized in research focused on the modulation of dopaminergic signaling. Its application extends to studying neuropsychiatric disorders and exploring therapeutic strategies for schizophrenia and related conditions. -
Dopamine D3?Receptor Ligand
Dopamine D3 receptor ligand-4 is a highly potent and selective ligand for the dopamine D3 receptor, exhibiting a Ki value of 0.5 nM. It demonstrates impressive selectivity for the D3 receptor over the D2 receptor, with a Ki of 7.43 nM. This compound is valuable for research applications focused on understanding dopamine-related pathways and potential therapeutic targets in neuropsychiatric disorders. -
PD3 Receptor Antagonist
S 33138 is a potent D3 receptor antagonist. This compound has demonstrated the ability to inhibit addictive behaviors in various animal models, as well as ameliorate cognitive deficits in rodent and primate models of schizophrenia and Parkinson's disease. S 33138 serves as a valuable tool for research applications focused on neurological disorders, advancing the understanding of pathophysiological mechanisms and potential therapeutic strategies. -
Dopamine Autoreceptor Agonist
PD 119819 is a selective dopamine autoreceptor agonist belonging to the benzopyran-4-one class. It modulates dopaminergic activity by inhibiting spontaneous locomotor activity and reducing brain dopamine synthesis. This compound is valuable for research into dopamine-related neurophysiology and the study of disorders influenced by dopamine receptor activity. -
Dopamine Receptor Agonist
(-)-UH 232 is a central dopamine receptor agonist with a primary action of modulating dopaminergic signaling. It has been shown to reduce the formation of 3,4-dihydroxyphenylalanine (DOPA) in striatal and limbic regions of the rat brain. This compound serves as a valuable tool for investigating neurological disorders, including Parkinson's disease and schizophrenia. -
Dopamine Receptor Agonist
RS-12254 is a dopamine receptor agonist that exerts hypotensive and diuretic effects through its regulation of blood pressure and electrolyte balance. This compound effectively lowers blood pressure and minimizes plasma norepinephrine levels, contributing to its diuretic and natriuretic properties. RS-12254 is valuable in research applications focused on cardiovascular regulation and sympathetic nerve activity modulation. -
D3R Antagonist
ST 198 is a selective D3 receptor (D3R) antagonist that demonstrates oral bioactivity. It effectively inhibits nicotine-induced conditioned place preference (CPP) at specific doses targeting D3R. This compound is valuable for research investigating neurological diseases and the mechanisms underlying dopaminergic signaling. -
D3R PAM-Antagonist
Dopamine D3 receptor antagonist-3 is a selective positive allosteric modulator-antagonist targeting the D3 dopamine receptor (D3R) that effectively penetrates the blood-brain barrier. It demonstrates robust antagonist activity in D3R-mediated β-arrestin recruitment assays, exhibiting an IC50 of 2.5 μM and a Kd of 0.49 μM, and in D3R-mediated Go-BRET assays, with an IC50 of 0.34 μM. This reagent is suitable for investigating neuropsychiatric disorders, including substance use disorder, providing valuable insights into D3R's role in these conditions. -
Dopamine Receptor Agonist
Razpipadon ((-)-PW0464) is a dopamine receptor partial agonist with a specific affinity for the D1 receptor. This compound is crucial for research into dopamine-mediated psychiatric disorders, as it allows for the investigation of receptor activity and its impact on neurochemical signaling. Razpipadon serves as a valuable tool for elucidating the role of dopamine in various neurological and psychiatric conditions. -
Dopamine D2 Receptor Antagonist
Bromopride hydrochloride is a selective, irreversible dopamine D2 receptor antagonist with oral bioactivity. It effectively crosses the blood-brain barrier to inhibit the vomiting center while promoting gastrointestinal motility by enhancing smooth muscle contraction. This compound is valuable for research into digestive system disorders, including gastric hypomotility, nausea, and vomiting, and demonstrates no harmful effects on abdominal wall healing in the context of postoperative abdominal infections. -
D2 Receptor Antagonist
SLV310 is an orally active antagonist of the dopamine D2 receptor, exhibiting a Ki value of 5 nM, and also acts as a serotonin reuptake inhibitor. It effectively antagonizes Apomorphine-induced climbing behavior and 5-HTP-induced serotonin syndrome in murine models, with an ED50 of 5.6 and 5.9 mg/kg, respectively. This compound serves as a valuable tool for antipsychotic research, particularly in studies related to schizophrenia. -
D2/D3 Receptor Agonist
N-Despropyl Ropinirole (SKF-104557) is a potent agonist targeting dopamine D2 and D3 receptors. As an active metabolite of Ropinirole, it exhibits full agonistic activity at human D2 and D3 receptors while acting as a partial agonist at the hD4 receptor. This compound is valuable for research applications investigating dopaminergic signaling and potential therapeutic strategies for diseases such as Parkinson's and schizophrenia. -
Dopamine D4 Receptor Antagonist,
CP-293019 is a selective antagonist of the dopamine D4 receptor, characterized by a Ki value of 3.4 nM. This compound effectively inhibits apomorphine-induced hyperactivity in rat models, making it a valuable tool for research into neuropharmacology and the role of dopamine receptors in behavioral studies. Its application extends to studies exploring the mechanisms underlying dopamine-related disorders. -
Dopamine Receptor Antagonist
Bromperidol decanoate is a dopamine receptor antagonist primarily utilized in the treatment of schizophrenia. Its notable biological activity includes the inhibition of dopaminergic pathways, which contributes to its antipsychotic effects. This compound is relevant in research focused on psychotropic drug development and the exploration of dopamine-related disorders. -
Dopamine Receptor Antagonist
Ordopidine is a selective dopamine D2 receptor antagonist that effectively inhibits hyperactivity induced by psychostimulants. This compound is valuable for neurological research, providing insights into the modulation of dopaminergic pathways and the study of related disorders. Its application may facilitate the exploration of therapeutic strategies for conditions such as schizophrenia and other dopamine-related disorders. -
D3R Antagonist
VK4-116 is a selective antagonist of the Dopamine D3 receptor (D3R) with a Ki value of 6.84 nM. This compound effectively inhibits Oxycodone-induced hyperlocomotion and locomotor sensitization in mouse models, demonstrating its potential as a therapeutic agent for addiction-related behaviors. Furthermore, VK4-116 has been shown to prevent the acquisition of Oxycodone-induced conditioned place preference (CPP) in rat models, highlighting its applications in addiction research. -
D2-receptor Agonist
(±)-N-Propylnorapomorphine functions as a dopamine D2-receptor agonist, selectively activating the D2 receptor pathway. This compound demonstrates significant biological activity related to dopaminergic signaling, making it valuable for research in neuropharmacology and the study of dopamine-related disorders. Its application extends to investigating the physiological and behavioral effects of dopamine modulation. -
Lisuride Analogue
Bromerguride is an analogue of the ergot-derived dopamine agonist Lisuride, functioning primarily as a central antidopaminergic agent. This compound is utilized in pharmacological research to investigate the modulation of dopaminergic pathways and their implications in neurological conditions. Its unique properties make it a valuable tool for studying dopamine receptor interactions and their effects on various biological systems. -
PPHT Derivatives
4-Amino-PPHT is a derivative of PPHT that selectively targets dopamine D-2 receptors, exhibiting a binding affinity characterized by a Ki value of 6.8 nM. This compound is essential for investigating the role of dopamine signaling in neuropharmacology and related research applications. It provides a valuable tool for studies focused on neuropsychiatric disorders and the development of therapeutic agents targeting dopamine receptors. -
Dopamine Receptor
CJB-090 dihydrochloride is a partial agonist targeting dopamine D3 receptors. This compound demonstrates unique partial agonist properties in vitro and has been shown to provoke yawning responses in monkeys with a history of cocaine use. CJB-090 is also effective in reducing the reinstatement of cocaine-induced behaviors, making it a valuable tool for studies on addiction and dopamine receptor functions. -
Dopamine Receptor Agonist
Dopamine D2 receptor agonist-2 is a selective agonist targeting the dopamine D2 receptor, exhibiting a binding affinity with a Ki value of 11.2 nM. This compound demonstrates biased agonism, making it a valuable tool for investigating mechanisms underlying antipsychotic effects. It is suitable for research applications focused on the modulation of dopamine signaling and the study of psychiatric disorders. -
Dopamine Receptor Antagonist
Dopamine D3 receptor antagonist-1 is a selective antagonist of the dopamine D3 receptor, exhibiting a binding affinity with a Ki value of 1.58 nM. This compound is of particular interest in the study of central nervous system disorders, as it may play a role in modulating dopaminergic signaling pathways. Its unique bitopic ligand properties suggest applications in researching both psychiatric and neurodegenerative conditions, providing valuable insights into therapeutic interventions. -
Dopamine Receptor
FAUC 3019 is a partial agonist of the dopamine D4 receptor. This compound demonstrates a significant stimulatory effect on penile erection in male rats, particularly at low concentrations. FAUC 3019 is a valuable tool for exploring the physiological mechanisms underlying erectile function and has potential applications in the study of sexual health and related disorders. -
Dopamine D2 Receptor Antagonist
Dehydrate haloperidol is a selective antagonist of the human dopamine D2 receptor, exhibiting a pKd of 8 and a pKi of 8. This compound is primarily utilized in research focused on schizophrenia and related disorders, providing insights into dopamine signaling pathways and their role in neuropsychiatric conditions. -
Dopamine Receptor
BP14979 is a selective agonist of the dopamine D3 receptor, primarily utilized in the investigation of neurological disorders. Its structural properties allow for the modulation of D3 receptor efficacy, making it a valuable tool in the development of ligands with enhanced selectivity and affinity. By understanding the differences in efficacy compared to D3 receptor antagonists, BP14979 offers significant potential for optimizing therapeutic agents in drug development. -
Stable Isotope
Pramipexole-d7-1 dihydrochloride is a deuterium-labeled analog of Pramipexole dihydrochloride, a selective agonist of dopamine D2-type receptors. This compound effectively penetrates the blood-brain barrier and exhibits Ki values of 2.2 nM, 3.9 nM, 0.5 nM, and 1.3 nM for the D2-type receptor, D2, D3, and D4 receptors, respectively. Pramipexole-d7-1 dihydrochloride is valuable for research on Parkinson's disease and restless legs syndrome, facilitating advanced studies in neuropharmacology and the pharmacokinetics of dopamine receptor interactions. -
D2 Receptor Partial Agonist
Dopamine D2 receptor agonist-3 is a selective partial agonist for the D2 receptor, exhibiting a pEC50 of 8.3. Additionally, it acts as an antagonist at the D3 receptor with a pEC50 of less than 5.5. This compound is valuable for research into dopamine receptor signaling pathways and may provide insights into neuropsychiatric disorders. -
Stable Isotope
Ropinirole-d7 hydrochloride is a deuterium-labeled analog of Ropinirole hydrochloride, functioning as a potent agonist for D2 and D3 dopamine receptors. With a Ki value of 29 nM for the D2 receptor, it demonstrates strong biological activity, exhibiting pEC50 values of 7.4, 8.4, and 6.8 for human D2, D3, and D4 receptors, respectively, while showing no affinity for D1 receptors. This compound is particularly relevant in research focused on Parkinson's disease and neuropharmacology. -
Dopamine Receptor Antagonist
Dopamine D3 receptor antagonist-2 is a selective antagonist for the dopamine D3 receptor, exhibiting a Ki value of 2.16 nM. This compound serves as a multitarget bitopic ligand and has potential applications in the study and treatment of various central nervous system disorders, including schizophrenia and addiction-related conditions. Its specificity for the D3 receptor makes it a valuable tool for research into dopamine-mediated neuropharmacology. -
Functionally Selective Ligand for Dopamine D2 Receptor
UNC10099984A is a functionally selective ligand for the dopamine D2 receptor, exhibiting a Ki value of 4.6 nM and an EC50 value of 6.2 nM for β-arrestin. This compound is particularly valuable for investigating central nervous system disorders associated with D2 receptor modulation, facilitating research into dopamine signaling pathways and their therapeutic implications. -
Dopamine Receptor Inhibitor
TISCH is a potent and selective iodinated ligand that targets CNS D1 dopamine receptors, demonstrating a high affinity with a Kd value of 0.205 nM in rat striatal tissue. Its ability to cross the blood-brain barrier allows for effective distribution in regions with substantial D1 receptor density, making it a valuable pharmacological tool for characterizing these receptors. Additionally, TISCH, when labeled with I-123, has potential applications as an in vivo imaging agent for studying D1 dopamine receptor function in the central nervous system. -
Dopamine Receptor Agonist
BAM-1110 is a dopamine receptor agonist that demonstrates dose-dependent antiparkinsonian effects in MPTP-treated monkey models of Parkinson's disease. Its ability to activate dopamine receptors makes it a valuable tool for investigating Parkinson's disease and other neurological disorders. Additionally, BAM-1110 is characterized by minimal side effects, enhancing its suitability for research applications in this field. -
Dopamine Receptor Agonist
CQP-201403 is a selective dopamine receptor agonist that activates dopamine receptors to modulate neurotransmission. This compound is primarily utilized in the study of neurological diseases, offering insights into dopaminergic signaling and potential therapeutic pathways. Its application in research facilitates the exploration of mechanisms underlying conditions such as Parkinson's disease and schizophrenia. -
Dopamine D3 Receptor Antagonist
SB-414796 is a selective antagonist of the dopamine D3 receptor, exhibiting potent inhibitory activity with a Ki value of 4 nM. This compound demonstrates significantly lower affinity for the D2 receptor, noted at 400 nM. It is capable of crossing the blood-brain barrier, making it suitable for investigating the role of dopamine D3 receptors in neuropharmacology and potential therapeutic applications related to related neuropsychiatric disorders. -
D3R/MOR Antagonist
D3R/MOR Antagonist 1, a dual antagonist targeting the D3 receptor and the mu-opioid receptor, exhibits affinities of Ki values at 46.5 nM and 691 nM, respectively. This compound is designed to potentially elicit analgesic effects while minimizing opioid misuse liability through D3R antagonism. Its unique mechanism makes it a valuable tool for research in pain management and substance use disorders. -
Dopamine D3 Receptor Antagonist
NGB 2904 hydrochloride is a selective antagonist of the dopamine D3 receptor, exhibiting a Ki value of 1.4 nM. This compound demonstrates a strong preference for the D3 receptor over other targets, including D2, 5-HT2, α1, D4, D1, and D5 receptors, as evidenced by significantly higher Ki values. NGB 2904 hydrochloride effectively antagonizes Quinpirole-stimulated mitogenesis, making it a valuable tool for research in dopamine signaling and related neurological studies. -
D3 receptor antagonist
U-99194 is a selective and potent antagonist of the dopamine D3 receptor. This compound effectively inhibits D3 receptor activation induced by endogenous dopamine and exogenous D3 agonists, as demonstrated by its ability to negate the IPSC-suppressive effects of the D3 agonist PD 128907 in rat hippocampal slices. U-99194 also significantly suppresses nicotine-induced tremors in mice, making it a valuable tool for investigating dopamine D3 receptor-related motor disorders, especially those involving kinetic tremors. -
Dopamine D2 Receptor Antagonist
Flupenthixol decanoate is a dopamine D2 receptor antagonist known for its antipsychotic properties. This compound is commonly utilized in research focused on schizophrenia and depression, enabling investigations into the underlying mechanisms of these psychiatric disorders. Its long-acting formulation supports studies on sustained therapeutic effects and dosing regimens.
